ARTICLE | Strategy
Breathing room in China
How AstraZeneca is building the market for COPD, asthma in China
May 11, 2015 7:00 AM UTC
AstraZeneca plc is investing in China to extend the market for treatment of chronic obstructive pulmonary disease and asthma beyond the acute care setting, which could greatly expand the company's growing respiratory franchise.
China represents a nexus of emerging markets and respiratory disorders, two of AstraZeneca's five "growth platforms." Indeed, China comprises AZ's second-largest market, accounting for about half of emerging markets sales and 9% of total sales...